M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 0.94385 USD -3.76% Market Closed
Market Cap: $100.7m

MaxCyte Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

MaxCyte Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
M
MaxCyte Inc
NASDAQ:MXCT
Inventory
$8.9m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
26%
Thermo Fisher Scientific Inc
NYSE:TMO
Inventory
$5.7B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Inventory
$2.7B
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Inventory
$401.8m
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Inventory
$1B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
7%
IQVIA Holdings Inc
NYSE:IQV
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MaxCyte Inc
Glance View

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
HIDDEN
Show

See Also

What is MaxCyte Inc's Inventory?
Inventory
8.9m USD

Based on the financial report for Dec 31, 2024, MaxCyte Inc's Inventory amounts to 8.9m USD.

What is MaxCyte Inc's Inventory growth rate?
Inventory CAGR 10Y
26%

Over the last year, the Inventory growth was -27%. The average annual Inventory growth rates for MaxCyte Inc have been 20% over the past three years , 19% over the past five years , and 26% over the past ten years .

Back to Top